Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study

Introduction: In the phase 3 RESORCE trial, regorafenib prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC) whose disease progressed on prior sorafenib. The prospective, observational REFINE study aimed to evaluate the safety and effectiveness of regorafenib...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Liver cancer (Basel ) 2024-12, p.1-31
Hauptverfasser:	Kim, Yoon Jun, Merle, Philippe, Finn, Richard S., Kudo, Masatoshi, Klümpen, Heinz-Josef, Lim, Ho Yeong, Ikeda, Masafumi, Granito, Alessandro, Masi, Gianluca, Gerolami, René, Cho, Sung Bum, Hsu, Chih-Hung, Huang, Yi-Hsiang, Jeng, Long-Bin, Kim, Do Young, Lin, Shi-Ming, Pinter, Matthias, Shao, Guoliang, Kato, Naoya, Kurosaki, Masayuki, Numata, Kazushi, Kuo, Kung-Kai, Mao, Yilei, Lin, Yih-Jyh, Zhu, Kangshun, Twumasi-Ankrah, Philip, Khan, Javeed, Awan, Maria, Ozgurdal, Kirhan, Qin, Shukui
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!